title: Comprehensive assessment of the association between DNA repair gene XRCC3 rs861539 C/T polymorphism and lung cancer risk.
abstract: A few case-control studies were performed to assess the association between X-ray repair cross-complementing group 3 (XRCC3) rs861539 C/T polymorphism and lung cancer susceptibility, but no consistent finding was reported. In the present study, we performed a meta-analysis of 14 case-control studies with a total of 7,869 lung cancer cases and 10,778 controls to provide a comprehensive assessment of the association between XRCC3 rs861539 C/T polymorphism and lung cancer risk. Pooled odds ratios (ORs) and corresponding 95 % confidence intervals (95 % CIs) were calculated to assess the strength of the association. Overall, there was no significant association between XRCC3 rs861539 C/T polymorphism and lung cancer risk under all genetic models [OR (95 % CI) for T versus C, 1.00 (0.89-1.13), P = 0.99; OR (95 % CI) for TT versus CC, 1.07 (0.81-1.41), P = 0.62; OR (95 % CI) for TT/CT versus CC, 0.95 (0.84-1.07), P = 0.39; OR (95 % CI) for TT versus CT/CC, 1.10 (0.86-1.39), P = 0.62]. In the subgroup analyses of both Asians and Caucasians, there was still no significant association between XRCC3 rs861539 C/T polymorphism and lung cancer risk under all genetic models (All P values were more than 0.05). However, there was an obvious association between XRCC3 rs861539 C/T polymorphism and decreased risk of lung cancer in the subgroup analysis of the mixed population (All P values were less than 0.05). In addition, there was some risk of publication bias in the meta-analysis, and there was obvious discrepancy in the findings between studies with large sample size and studies with small sample size in the meta-analysis. The meta-analysis indicates that the association between XRCC3 rs861539 C/T polymorphism and lung cancer risk is still uncertain owing to the obvious discrepancy in the findings between studies with large sample size and studies with small sample size. More studies with large sample size are needed to further assess the association.
authors: Department of Oncology, Chongming Branch of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 202150, China.
authors: Gang
authors: G
authors: Ding
authors: Weiguo
authors: W
authors: Xu
authors: Hongwei
authors: H
authors: Hua
authors: Qian
authors: Q
authors: Huang
authors: Hongxiang
authors: H
authors: Liang
authors: Yufeng
authors: Y
authors: Ni
authors: Zhaoheng
authors: Z
authors: Ding
mesh_terms: D016022:Case-Control Studies; D004260:DNA Repair / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics*; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors
chemical_list: D004268:DNA-Binding Proteins; C110901:X-ray repair cross complementing protein 3
references: Cancer Lett. 2004 Sep 15;213(1):67-72
references: 15312685
references: Tumour Biol. 2012 Dec;33(6):2385-92
references: 22965879
references: J Cell Biol. 2007 Oct 8;179(1):53-63
references: 17923529
references: Lancet. 2011 Nov 12;378(9804):1727-40
references: 21565398
references: Lung Cancer. 2011 Aug;73(2):138-46
references: 21195504
references: JAMA. 2008 May 28;299(20):2423-36
references: 18505952
references: Zhonghua Jie He He Hu Xi Za Zhi. 2007 Dec;30(12):936-40
references: 18336773
references: Environ Mol Mutagen. 2004;44(1):74-82
references: 15199549
references: Wei Sheng Yan Jiu. 2011 Mar;40(2):187-90
references: 21560306
references: Hum Mol Genet. 2007 Dec 15;16(24):3117-27
references: 17901044
references: N Engl J Med. 2008 Sep 25;359(13):1367-80
references: 18815398
references: Carcinogenesis. 2006 May;27(5):997-1007
references: 16308313
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120
references: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references: 13655060
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Genet Test Mol Biomarkers. 2012 Jun;16(6):640-3
references: 22299591
references: Lancet Oncol. 2011 Apr;12(4):399-408
references: 20951091
references: Tumour Biol. 2012 Dec;33(6):1973-81
references: 22797821
references: Cancer Res. 2008 Apr 15;68(8):3049-56
references: 18413776
references: Anticancer Res. 2008 Sep-Oct;28(5B):2941-6
references: 19031937
references: Cancer Lett. 2003 Mar 10;191(2):171-8
references: 12618330
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: PLoS One. 2011;6(5):e20055
references: 21647442
references: J Thorac Oncol. 2012 Jun;7(6):954-62
references: 22525558
references: Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):911-2
references: 11489761
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Carcinogenesis. 2006 Mar;27(3):560-7
references: 16195237
references: Carcinogenesis. 2004 Dec;25(12):2433-41
references: 15333465
references: Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3081-9
references: 18990748
references: BMC Cancer. 2007 Aug 16;7:162
references: 17705814